SC
CSTL icon

SummitTX Capital’s Castle Biosciences CSTL Stock Holding History

SummitTX Capital’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.88M Buy
79,018
+11,985
+18% +$267K 0.05% 345
2026
Q1 		$1.65M Buy
67,033
+49,623
+285% +$1.63M 0.05% 339
2025
Q4 		$677K Sell
17,410
-27,590
-61% -$889K 0.02% 483
2025
Q3 		$1.02M Buy
+45,000
New +$914K 0.04% 380

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SummitTX Capital's CSTL Position: Q2 2026 in Review

SummitTX Capital increased its Castle Biosciences (CSTL) stake by 18% in Q2 2026, buying an estimated $267K and bringing the position to 79,018 shares worth $1.88M. The position accounts for 0.05% of the portfolio, ranked #345.

SummitTX Capital first reported a position in CSTL in Q3 2025 and has held it in 4 quarters since. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • SummitTX Capital held 79,018 shares of Castle Biosciences worth $1.88M as of Q2 2026.
  • SummitTX Capital bought 11,985 Castle Biosciences shares in Q2 2026, an estimated $267K.
  • Castle Biosciences made up 0.05% of SummitTX Capital's portfolio in Q2 2026, its #345 holding.
  • SummitTX Capital first reported a position in Castle Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.